Drug Profile
Recombinant interferon alpha-2a - Amoytop Biotech/BioGeneric Pharma
Alternative Names: rhIFNα-2aLatest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Amoytop Biotech; BioGeneric Pharma
- Developer Amoytop Biotech
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon alfa 2a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Unspecified in China
- 06 Jan 2016 Clinical trials in Undefined indication in China (unspecified route)